Nemvaleukin

Phase 2Protein / enzyme

MMural Oncology, Inc

Nemvaleukin is one of 3 biologic programs targeting Tumor Microenvironment. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Tumor MicroenvironmentActive, not recruiting

Tumor MicroenvironmentPhase 2

Active, not recruiting

Competition

Competitive Landscape

2 competitors in Tumor Microenvironment

#DrugCompanyPhaseTrials

Keytruda

Merck & Co.

Phase 2

2 2

Nemvaleukin

MMural Oncology, Inc

Phase 2

1 3

Lifei Xiaoji Wan

HHenan University of Traditional Chinese Medicine

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Head and Neck Cancer1 trial

A Study of ALKS 4230 (Nemvaleukin Alfa) With Pembrolizumab in Head and Neck Cancer

Completed·MMural Oncology, Inc·Phase 2·NCT04144517·14 enrolled

Mucosal Melanoma1 trial

Nemvaleukin Alfa Monotherapy and in Combination With Pembrolizumab in Patients With Advanced Cutaneous or Mucosal Melanoma - ARTISTRY-6

Terminated·MMural Oncology, Inc·Phase 2·NCT04830124·173 enrolled

Tumor Microenvironment1 trial

Less Frequent IV Dosing & Tumor Microenvironment (TME) Study of Nemvaleukin Alfa (ALKS 4230) Monotherapy and in Combination With Pembrolizumab (ARTISTRY-3)

Active, not recruiting·MMural Oncology, Inc·Phase 1/2·NCT04592653·78 enrolled

Ovarian Cancer1 trial

Phase 3 Study of Nemvaleukin Alfa in Combination With Pembrolizumab in Patients With Platinum-Resistant Epithelial Ovarian Cancer (ARTISTRY-7)

Terminated·MMural Oncology, Inc·Phase 3·NCT05092360·456 enrolled

Sources

References

[1]
ClinicalTrials.gov — 4 trial records for Nemvaleukin. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Nemvaleukin compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Nemvaleukin. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Mural Oncology, Inc company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Protein / enzyme[2]
Highest Phase: Phase 2[1]
Company: MMural Oncology, Inc

Nemvaleukin

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Head and Neck Cancer1 trial

Mucosal Melanoma1 trial

Tumor Microenvironment1 trial

Ovarian Cancer1 trial

References

Drug Info

Quick Facts

Related News